Data from multiple sources - Curated by Toby Galbraith - Last updated 06 June 2017

Latest news articles

Added 4 months ago Drug news

Zoptrex (zoptarelin doxorubicin) fails to meet primary endpoint in endometrial cancer- Aeterna Zentaris

Aeterna Zentaris announced that the ZoptEC Phase III clinical study of Zoptrex (zoptarelin doxorubicin) in women with locally advanced, recurrent...

Added 4 years ago Drug news

AEZS-108 to commence Phase III trial for Endometrial Cancer

The FDA has approved an upcoming Phase III registration trial in Endometrial Cancer for AEZS-108 from Aeterna Zentaris Inc. This...

Search all news articles for Cancer of other female genital organs

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Breakthrough Cancer Pain Learning Zone

Invitation to watch the online broadcast of the BeCOn OWN event 'Shifting paradigms in BTcP management' on June 16 2017.

Visit Breakthrough Cancer Pain Learning Zone

Chronic Obstructive Pulmonary Disease (COPD)

View highlights from recent congresses presented in new expert videos with leading physicians.

+ 3 more

Visit Chronic Obstructive Pulmonary Disease (COPD)


Guidelines for the Diagnosis and Management of Vulval Carcinoma

This document is intended to fulfil several objectives: - To promote a uniformly high standard of care for women with...

Added 3 years ago

Search all guidelines for Cancer of other female genital organs

Journal articles

Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer.

Olaparib is the first oral poly(ADP-ribose) polymerase inhibitor to be approved as maintenance monotherapy for treatment of patients with platinum-sensitive relapsed BRCA-mutated (BRCAm) serous ovarian cancer.

Added 5 months ago

Olaparib for the treatment of epithelial ovarian cancer.

Introduction: Despite recent advances in the management of epithelial ovarian cancer, overall survival rates remain poor, and there is a pressing need to develop novel therapeutic agents and maintenance strategies ...

Added 1 year ago

Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer.

Background: Olaparib (AZD2281), a PARP-1/2 inhibitor, has been extensively investigated in clinical trials. However, limited clinical data are available about...

Added 2 years ago

Search all journal articles for Cancer of other female genital organs

Clinical trials

PH3 Study of IMGN853 vs Investigator's Choice of Chemotherapy in Women With FRa+ Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer (FORWARD I)

This is a Phase 3, open label, randomized study designed to compare the safety and efficacy of IMGN853 to that of selected single-agent chemotherapy (Investigator's choice) in women with platinum-resistant FR-alpha positive advanced...

Added 5 months ago

Search all clinical trials for Cancer of other female genital organs
Fiona Holland

Fiona worked in the fitness and wellness industry in the US for 13 years, supporting behaviour change in a variety of settings. Fiona’s research interests lie broadly within health and wellbeing. She is particularly interested in qualitative methodologies in the areas of body image ... Read more

What to say and do when someone has cancer

Ahead of World Cancer Day on Saturday (February 4), Fiona Holland, Psychology Lecturer, discusses what to say and what not to say to someone with cancer.